Urist Marshall, EVP of Research and Investments at Royalty Pharma plc ($RPRX), sold about $9.6 million in company shares across 12 open market transactions over the past year. His latest sale happened on January 30, 2026. These insider sales rank him 1,164th out of 11,678 individuals by total value, topping the average of $8.6 million per seller over roughly 6.4 trades. Urist Marshall recorded no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 11, 2026 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | A | Class A Ordinary Shares | 19970 | $0.00 | 46,388.0000 | 564,455,000 | 75.59% | 0.00% |
| Jan. 30, 2026 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $41.09 | 26,418.0000 | 564,455,000 | 43.09% | 0.00% |
| Jan. 23, 2026 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $40.26 | 46,418.0000 | 564,455,000 | 30.11% | 0.00% |
| Jan. 16, 2026 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $39.52 | 66,418.0000 | 564,455,000 | 23.14% | 0.00% |
| Jan. 9, 2026 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $40.78 | 86,418.0000 | 564,455,000 | 18.79% | 0.00% |
| Jan. 2, 2026 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $38.48 | 106,418.0000 | 564,455,000 | 15.82% | 0.00% |
| Dec. 26, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $39.32 | 126,418.0000 | 566,754,000 | 13.66% | 0.00% |
| Dec. 19, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $38.38 | 146,418.0000 | 566,754,000 | 12.02% | 0.00% |
| Dec. 16, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 20000 | $38.32 | 166,418.0000 | 566,754,000 | 10.73% | 0.00% |
| Dec. 5, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 23334 | $39.15 | 186,418.0000 | 566,754,000 | 11.12% | 0.00% |
| Dec. 5, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 18242 | $39.15 | 186,418.0000 | 566,754,000 | 8.91% | 0.00% |
| Dec. 1, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 18242 | $39.90 | 227,994.0000 | 566,754,000 | 7.41% | 0.00% |
| Dec. 1, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 23333 | $39.93 | 227,994.0000 | 566,754,000 | 9.28% | 0.00% |
| Nov. 7, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | C | LP interests in RPI US Partners 2019, LP | 16000 | $0.00 | 247,412.0000 | 566,754,000 | 6.07% | 0.00% |
| Nov. 5, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | A | Class A Ordinary Shares | 4626 | $0.00 | 269,569.0000 | 566,754,000 | 1.75% | 0.00% |
| Nov. 7, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | C | Class A Ordinary Shares | 160000 | $0.00 | 269,569.0000 | 566,754,000 | 146.03% | 0.03% |
| Aug. 8, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | G | LP interests in RPI US Partners 2019, LP | 3000 | $0.00 | 263,412.0000 | 594,108,000 | 1.13% | 0.00% |
| Aug. 6, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | A | Class A Ordinary Shares | 2772 | $0.00 | 104,943.0000 | 594,108,000 | 2.71% | 0.00% |
| May 16, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | A | Class E Ordinary Shares | 1356528 | $0.00 | 1,356,528.0000 | 594,108,000 | 9999.99% | 0.23% |
| May 8, 2025 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | A | Class A Ordinary Shares | 36484 | $0.00 | 102,171.0000 | 594,108,000 | 55.54% | 0.01% |
| Aug. 12, 2024 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | G | LP interests in RPI US Partners 2019, LP | 2182 | $0.00 | 126,412.0000 | 602,900,000 | 1.70% | 0.00% |
| Feb. 22, 2023 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | S | Class A Ordinary Shares | 23333 | $37.30 | 65,687.0000 | 437,972,000 | 26.21% | 0.01% |
| Feb. 17, 2023 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | C | Class A Ordinary Shares | 70000 | $0.00 | 89,020.0000 | 437,972,000 | 368.03% | 0.02% |
| Feb. 17, 2023 | Royalty Pharma plc | $RPRX | Urist Marshall | EVP, Research & Investments | C | LP interests in RPI US Partners 2019, LP | 7000 | $0.00 | 128,594.0000 | 437,972,000 | 5.16% | 0.00% |